A novel bispecific antibody therapy against colorectal cancer.
'Colorectal cancer' (CRC) is one of the leading causes of cancer-related deaths in Europe. A new antibody-based therapy developed using novel patient-derived screening technology, promises to specifically treat CRC patients with reduced side-effects.
| Publicat a: | Research'eu results magazine March, 60 (2017). |
|---|---|
| Format: | Article |
| Idioma: | English |